Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | PLD2 | O14939 | 5/20 | 0.45 |
| ▸ | PLD1 | Q13393 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870207 | 1.00 | HTT (0.49) | HTTALDH1A1MTNR1AMTNR1BPLD2 | |
| SCHEMBL28499858 | 1.00 | HTT (0.49) | HTTALDH1A1MTNR1AMTNR1BPLD2 | |
| SCHEMBL22869755 | 0.88 | HSD11B1 (0.56) | ALDH1A1PLD2PLD1CHRM1DRD2 | |
| SCHEMBL30870356 | 0.88 | POLB (0.48) | PLD2PLD1CHRM1DRD2HPGD | |
| SCHEMBL28509295 | 0.88 | HSD11B1 (0.56) | ALDH1A1PLD2PLD1CHRM1DRD2 | |
| SCHEMBL30870157 | 0.88 | HSD11B1 (0.49) | ALDH1A1PLD2PLD1CHRM1DRD2 | |
| SCHEMBL22869686 | 0.88 | POLB (0.48) | PLD2PLD1CHRM1DRD2HPGD | |
| SCHEMBL22869425 | 0.88 | HSD11B1 (0.49) | ALDH1A1PLD2PLD1CHRM1DRD2 | |
| SCHEMBL30870121 | 0.88 | HSD11B1 (0.56) | ALDH1A1PLD2PLD1CHRM1DRD2 | |
| SCHEMBL28503359 | 0.88 | POLB (0.48) | PLD2PLD1CHRM1DRD2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002250-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP4X1, CYP11B2 | HTT 3716/4885ALDH1A1 330/4885MTNR1A 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.